Citius Pharmaceuticals 8-K Report: Key Updates from January 2025
Based on the provided XML section of the financial report, here are the key pieces of information extracted:
- Entity Information:
- Name: Citius Pharmaceuticals, Inc.
- CIK (Central Index Key): 0001506251
- SEC File Number: 001-38174
- EIN (Employer Identification Number): 27-3425913
- Address: 11 Commerce Drive, 1st Floor, Cranford, NJ 07016
- Phone Number: 908-967-6677
- Report Type and Date:
- Filing Type: 8-K (a current report to announce major events)
- Filing Date: January 7, 2025
- Stock Information:
- Common Stock Par Value: $0.001
- Ticker Symbol: CTXR
- Exchange: NASDAQ
- Financial Context:
- The report is filed as of January 7, 2025, indicating the information contained is relevant to that specific date.
- Unit of Measurement:
- The financial data is reported in US Dollars (USD) and shares.
- The report includes a measure of USD in relation to shares (USD/Shares).
Insights:
- The report is likely to contain significant updates about Citius Pharmaceuticals, which may include developments regarding financial performance, corporate governance, or material events that shareholders need to be aware of.
- The use of an 8-K filing indicates that there may have been notable corporate actions or events occurring up to the filing date that could impact investor perception and company valuation.
- The company is publicly traded on NASDAQ, which means it is subject to strict regulatory reporting requirements, providing a layer of transparency for investors.
This information is crucial for investors, analysts, and stakeholders in understanding the company's current status and operational context.